Virtual Library

Start Your Search

H. Li



Author of

  • +

    P1.06 - Poster Session with Presenters Present (ID 458)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P1.06-022 - Clinical Characteristics of Survival Outliers in Stage IV Adenocarcinoma Lung Cancer Patients (ID 4304)

      14:30 - 15:45  |  Author(s): H. Li

      • Abstract
      • Slides

      Background:
      Lung cancer is the leading cause of cancer deaths among men and women in Canada. Many lung cancer patients are diagnosed at advanced stages of disease, which is associated with poor survival outcomes. The mean survival of stage IV non-small cell lung cancer (NSCLC) patients is typically less than 12 months; however, there appears to be a small subset of patients with advanced disease that live substantially longer than the norm. Our study aims to determine whether certain clinical characteristics correlate with longer survival in stage IV NSCLC patients.

      Methods:
      Data on 1803 stage IV NSCLC patients (1291 adenocarcinoma, 512 squamous cell carcinoma) from 1999-2011 were extracted from the Glans Look Lung Cancer database. Adenocarcinoma data is presented here; squamous cell carcinoma data analysis is ongoing. Clinical characteristics such as age, gender, ethnicity, smoking history, histology, molecular testing, metastatic disease, treatments, and socioeconomic factors were compared between survival outliers and patients with average survival. Survival outliers were defined as those patients who lived > 5 years, or greater than 2 standard deviations from mean survival (42.1 months).

      Results:
      In the survival outlier group, there were 25 patients who lived >5 years, and 59 who lived >42.1 months. Survival outliers included a higher percentage of females, had a smaller smoking history, smaller tumour size at diagnosis, received more treatment lines, and had lower metastatic disease burden at diagnosis (P<0.05 in the outlier group with survival >42.1 months). Upon further characterization of metastatic disease, there appears to be survival outliers associated with no liver metastases and less sites of metastases at diagnosis, as well as with stage M1a disease compared to stage M1b.

      Conclusion:
      Adenocarcinoma patients with localized and lower metastatic disease burden and no liver metastases at the time of diagnosis appeared to live longer than their counterparts. Further statistical analysis is ongoing to determine the significance of other clinical characteristics with respect to survival. The present study will help us better understand the importance of various clinical parameters and their association with survival, in hopes of improving outcomes for lung cancer patients in the future.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.